12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bavituximab: Phase II data

Top-line data from an open-label, U.S. and Ukrainian Phase II trial in 70 previously untreated stage IV pancreatic cancer patients showed that first-line treatment with bavituximab plus gemcitabine led to a median OS, the primary endpoint, of 5.6 months vs. 5.2 months for gemcitabine alone. On a secondary endpoint, bavituximab plus gemcitabine led to an ORR of 28% vs. 13% for gemcitabine alone. Peregrine did not...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >